Page 78 - 《中国药房》2023年9期
P. 78

守,当其发生基因突变和异常表达时,则会导致炎症、免                                螺环氧化吲哚类化合物的无催化剂合成及其抗白血病
          疫缺陷和肿瘤等多种疾病            [17―19] 。当细胞因子在细胞表                活性[J]. 合成化学,2019,27(6):451-455.
          面与其受体结合,致使 JAK2 激酶 C 端的酪氨酸残基磷                       [ 9 ]  吴相欢,吴丹,王关炼,等. 新型双螺环吡咯酮氧化吲哚
          酸化,进而招募 STAT3 致其磷酸化,从而形成的磷酸二                             并二氢色原酮类化合物的合成[J]. 合成化学,2020,28
                                                                  (6):537-542.
          聚体可迅速进入细胞核,调控下游相关基因表达或与其
                                                              [10]  CHEN S,JING Y,LIU X L,et al. One-pot multicompo‐
                                                  [17]
          他转录激活因子相互作用调控下游基因表达 。已有
                                                                   nent construction of chromanone-fused pyrrolidinyl spiro‐
          相关文献证实,JAK2/STAT3 信号通路可调控下游基因
                                                                   oxindole collections through a decarboxylative 1,3-dipolar
          Bcl-2、Bax的表达,后两者属于Bcl-2基因家族,与肿瘤细
                                                                   [3 + 2]cycloaddition reaction[J]. Synth Commun,2019,49
          胞凋亡密切相关;Bcl-2 为抗凋亡蛋白,Bax 为促凋亡蛋
                                                                  (18):2425-2435.
          白,两者相互作用共同调控细胞凋亡                [20―22] 。本研究结果      [11]  GREEN A C,OLSEN C M. Cutaneous squamous cell car‐
          显 示 ,经 3m 干 预 后 ,A431、Colo-16 细 胞 中 JAK2、                cinoma:an  epidemiological  review[J].  Br  J  Dermatol,
          STAT3、Bcl-2 mRNA 表达水平,JAK2、STAT3 蛋白磷酸                    2017,177(2):373-381.
          化水平和 Bcl-2 蛋白表达水平均显著下调,Bax mRNA                     [12]  徐圣文. 二氢色原酮并环戊烷螺环化合物的不对称合成
          和蛋白表达水平均显著上调。这提示 3m 可通过 JAK2/                            及其抗肿瘤活性研究[D]. 贵阳:贵州大学,2020.
          STAT3 信号通路调控下游 Bcl-2 基因家族诱导细胞                       [13]  OGATA  D,TSUCHIDA  T.  Systemic  immunotherapy  for
          凋亡。                                                      advanced  cutaneous  squamous  cell  carcinoma[J].  Curr
              综上所述,二氢色原酮拼接多环吡咯螺环氧化吲哚                               Treat Options Oncol,2019,20(4):30.
          类化合物 3m 可呈剂量依赖性地抑制 cSCC 的 A431、                     [14]  LEAL-ESTEBAN L C,FAJAS L. Cell cycle regulators in
                                                                   cancer cell metabolism[J]. Biochim Biophys Acta Mol Basis
          Colo-16细胞增殖、克隆形成、迁移、侵袭能力,其作用机
                                                                   Dis,2020,1866(5):165715.
          制与抑制 JAK2/STAT3 信号通路活性,诱导细胞凋亡
                                                              [15]  OBENG  E.  Apoptosis (programmed  cell  death)  and  its
          有关。
                                                                   signals :a review[J]. Revista Brasleira De Biol,2021,81
          参考文献                                                    (4):1133-1143.
          [ 1 ]  CORCHADO-COBOS  R,GARCÍA-SANCHA  N,          [16]  KETELUT-CARNEIRO N,FITZGERALD K A. Apoptosis,
               GONZÁLEZ-SARMIENTO  R,et  al.  Cutaneous  squa‐     pyroptosis,and necroptosis-oh my! the many ways a cell
               mous  cell  carcinoma:from  biology  to  therapy[J].  Int  J   can Die[J]. J Mol Biol,2022,434(4):167378.
               Mol Sci,2020,21(8):2956.                       [17]  BANERJEE S,BIEHL A,GADINA M,et al. JAK-STAT
          [ 2 ]  FIRNHABER  J  M.  Basal  cell  and  cutaneous  squamous   signaling  as  a  target  for  inflammatory  and  autoimmune
               cell carcinomas:diagnosis and treatment[J]. Am Fam     diseases:current and future prospects[J]. Drugs,2017,77
               Physician,2020,102(6):339-346.                     (5):521-546.
          [ 3 ]  FARBERG A S,FITZGERALD A L,IBRAHIM S F,et al.   [18]  XIN P,XU X Y,DENG C J,et al. The role of JAK/STAT
               Current methods and caveats to risk factor assessment in   signaling pathway and its inhibitors in diseases[J]. Int
               cutaneous squamous cell carcinoma (cSCC):a narrative   Immunopharmacol,2020,80:106210.
               review[J].  Dermatol  Ther (Heidelb),2022,12(2):  [19]  MENGIE AYELE  T,TILAHUN  MUCHE  Z,BEHAILE
               267-284.                                            TEKLEMARIAM A,et al. Role of JAK2/STAT3 signaling
          [ 4 ]  STRATIGOS A J,GARBE C,DESSINIOTI C,et al. Euro‐   pathway  in  the  tumorigenesis,chemotherapy  resistance,
               pean interdisciplinary guideline on invasive squamous cell   and treatment of solid tumors:a systemic review[J]. J
               carcinoma  of  the  skin:part  1.  epidemiology,diagnostics   Inflamm Res,2022,15:1349-1364.
               and prevention[J]. Eur J Cancer,2020,128:60-82.  [20]  TANG  C,ZHAO  C  C,YI  H,et  al.  Traditional  Tibetan
          [ 5 ]  DROLL S,BAO X M. Oh,the mutations you’ll acquire!   medicine  in  cancer  therapy  by  targeting  apoptosis  path‐
               A systematic overview of cutaneous squamous cell carci‐  ways[J]. Front Pharmacol,2020,11:976.
               noma[J]. Cell Physiol Biochem,2021,55(S2):89-119.  [21]  BALACHANDRAN  C,ARUN  Y  ,SANGEETHA  B,et
          [ 6 ]  CLAVEAU  J,ARCHAMBAULT  J,ERNST  D  S,et  al.     al.  In  vitro  and  in  vivo  anticancer  activity  of  2-acetyl-
               Multidisciplinary  management  of  locally  advanced  and   benzylamine  isolated  from Adhatoda  vasica  L.  leaves[J].
               metastatic  cutaneous  squamous  cell  carcinoma[J].  Curr   Biomed Pharmacother,2017,93:796-806.
               Oncol,2020,27(4):e399-e407.                    [22]  HAFEZI  S,RAHMANI  M.  Targeting  Bcl-2  in  cancer:
          [ 7 ]  董维维,王先恒,宋继庭,等. 基于天然产物的抗肿瘤缀                        advances,challenges,and perspectives[J]. Cancers (Basel),
               合物的研究进展[J]. 化学研究与应用,2022,34(3):                     2021,13(6):1292.
               460-467.                                                     (收稿日期:2022-09-29  修回日期:2023-03-29)
          [ 8 ]  刘婷婷,岳静,陈爽,等. 新型二氢色原酮拼接多环吡咯                                                       (编辑:唐晓莲)



          · 1092 ·    China Pharmacy  2023 Vol. 34  No. 9                              中国药房  2023年第34卷第9期
   73   74   75   76   77   78   79   80   81   82   83